National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

Danaei, Goodarz; Finucane, Mariel M.; Lu, Yuan; Singh, Gitanjali; Cowan, Melanie J.; Paciorek, Christopher J.; Lin, Hsien Ho; Farzadfar, Farshad; Khang, Young-Ho; Stevens, Gretchen A; Rao, Mayuree; Ali, Mohammed K.; Riley, Leanne M; Robinson, Carolyn A. Jost; Ezzati, Majid

doi:10.1016/s0140-6736(11)60679-x

Cited by 3,210 publications

(2,275 citation statements)

References 40 publications

Supporting

Mentioning

2,115

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, improved primary prevention risk factor control (reduced smoking, increased aspirin and statin use) has likely contributed to altered atherosclerosis burden with relatively less large‐vessel plaque rupture, potentially leading to less adverse arterial remodeling/obstructive CAD,17 while increasing rates of obesity18 and diabetes mellitus19 may contribute to increasing prevalence of CMD or pathology 20, 21…”

Section: Inoca—prevalencementioning

confidence: 99%

Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?

Herscovici

Sedlak

Wei

et al. 2018

JAHA

140

View full text Add to dashboard Cite

Section: Inoca—prevalencementioning

confidence: 99%

Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?

Herscovici

Sedlak

Wei

et al. 2018

JAHA

140

View full text Add to dashboard Cite

“…The presence of diabetes mellitus increases the incidence of cardiovascular diseases (CVDs) and risk of death. This represents a huge burden on health care and social economy 1. Management of fasting plasma glucose (FPG) levels associated with incident CVD and all‐cause mortality in the general population is an ongoing challenge for primary health care decision makers.…”

Section: Introductionmentioning

confidence: 99%

Visit‐to‐Visit Variability of Fasting Plasma Glucose and the Risk of Cardiovascular Disease and All‐Cause Mortality in the General Population

Wang

Liu

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundThe association of short‐term variability of fasting plasma glucose (FPG) and mortality has been well investigated. However, the relationships between visit‐to‐visit variability of FPG over longer periods of follow‐up and cardiovascular disease (CVD) and all‐cause mortality are unclear. This study aimed to investigate these relationships.Methods and ResultsThe current analysis included 53 607 Chinese participants (mean age, 49.10 years) who were free of CVD in the Kailuan study. Participants were divided into 4 categories by quartiles of visit‐to‐visit variability of FPG. Visit‐to‐visit variability of FPG was defined as the coefficient of variation of 3 values of FPG that were measured from the examination periods of 2006 to 2007, 2008 to 2009, and 2010 to 2011. Cox proportional hazards models were used to calculate hazard ratios and 95% confidence intervals for CVD and all‐cause mortality. After a mean follow‐up of 4.93 years, 4261 individuals developed CVD and 1545 individuals died. The incidence of CVD and all‐cause mortality was 5.04 and 5.85 per 1000 person‐years, respectively. After adjusting for mean FPG and other potential confounders, individuals in the highest quartile of variability of FPG compared with participants in the lowest quartile showed a 26% greater risk of developing CVD (hazard ratio, 1.26; 95% confidence interval, 1.08–1.47) and a 46% greater risk for all‐cause mortality (hazard ratio, 1.46; 95% confidence interval, 1.25–1.70).ConclusionsIndependent of mean FPG and other baseline parameters, elevated visit‐to‐visit variability of FPG significantly increases the risk of CVD and all‐cause mortality in the general population. Measuring long‐term visit‐to‐visit variability of FPG is helpful for predicting the risk for CVD and all‐cause mortality.

show abstract

“…According to the analysis results of global data, the prevalence of diabetes melllitus in adults was about 153 million in 1980 and 347 million in 2008 [1]. It is estimated to increase to 439 million in 2030, with a 69% increase in developing countries and 20% in developed countries [2].…”

Section: Introductionmentioning

confidence: 99%

Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials

Wang

Zhang

HaiLi

et al. 2017

Food & Nutrition Research

View full text Add to dashboard Cite

The present study was designed to systematically evaluate the clinical efficacy and safety of garlic supplement in the management of type 2 diabetes mellitus (T2DM). PubMed, EMBASE, the Cochrane Library, and China National Knowledge Internet (CNKI) were searched for relevant randomized controlled trials (RCTs) by using the terms garlic and T2DM up to April 2017. The quality of included RCTs was assessed by the Cochrane tool of risk of bias, and data of outcomes were pooled by REVMAN 5.3. Clinical factors were handled by meta-regression and subgroup analysis, and risk of publication bias was explored by inverted funnel plots. Nine RCTs involving 768 T2DM patients were included in the meta-analysis, and the dose of daily garlic (allicin) supplement ranged from 0.05g to 1.5g. A significant reduction in the level of fasting blood glucose in 1–2 weeks [SMD = −1.61, 95%CI (−2.89, −0.32)], 3–4 weeks [SMD = −2.87, 95%CI (−4.74, −1.00)], 12 weeks [SMD = −9.57, 95%CI (−12.39, −6.75)], and 24 weeks [SMD = −21.02, 95%CI (−32.47, −9.57)] was achieved in favour of the garlic group rather than the control group. Significantly decreased fructosamine and glycated hemoglobin (both in 12 and 24 weeks) were also found in garlic group. Meanwhile, significantly improved blood liquids of total cholesterol [SMD = −1.93, 95%CI (−2.98, −0.87), 3–4 weeks], high density lipoprotein [SMD = −0.41, 95%CI (−0.83, −0.00), 3–4 weeks] and low density lipoprotein [SMD = −3.47, 95%CI (−5.76, −1.18), 12 weeks] were confirmed after garlic administration. There was no significant difference in complications. Current data confirms that garlic supplement plays positive and sustained roles in blood glucose, total cholesterol, and high/low density lipoprotein regulation in the management of T2DM. Abbreviations: T2DM = type 2 diabetes mellitus; RCT = randomized controlled trial; SMD = standard mean difference; CI = confidence interval; FBG = fasting blood glucose; HbA1c = glycated hemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein.

show abstract

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

Cited by 3,210 publications

References 40 publications

Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?

Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?

Visit‐to‐Visit Variability of Fasting Plasma Glucose and the Risk of Cardiovascular Disease and All‐Cause Mortality in the General Population

Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About